57th European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

Helsinki, Finland 14 May 2025 - 17 May 2025

Long-term odevixibat shows sustained benefits in ALGS

20 Jun 2025 by

Long-term treatment with odevixibat led to sustained improvements in pruritus scores and reductions in serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), based on a pooled analysis of the phase III ASSERT and ASSERT-EXT studies presented at ESPGHAN 2025.

Long-term odevixibat shows sustained benefits in ALGS

20 Jun 2025

Study ties energy drink intake to unhealthy lifestyle in young individuals

19 Jun 2025 by

A study presented at ESPGHAN 2025 reports that schoolchildren who consume energy drinks have unhealthier lifestyles and a different cardiovascular risk profile than their counterparts who do not or rarely consume energy drinks.

Study ties energy drink intake to unhealthy lifestyle in young individuals

19 Jun 2025

Childhood adversity may lead to adult obesity

17 Jun 2025 by

Adverse childhood experiences (ACEs), such as abuse, neglect, and household dysfunction, appear to contribute to the development of obesity during adulthood, suggests an Iraq study presented at ESPGHAN 2025.

Childhood adversity may lead to adult obesity

17 Jun 2025

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD

17 Jun 2025 by

In paediatric patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), treatment with GLP-1 receptor agonists (RAs) results in a decrease in depression and substance use, as shown in a study presented at ESPGHAN 2025.

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD

17 Jun 2025

Final VEDOKIDS data: Remission with maintenance vedolizumab durable in UC, less so in CD

14 Jun 2025 by

Maintenance treatment with vedolizumab proved safe and effective in paediatric inflammatory bowel disease (IBD), with long-term remission achieved more frequently in children with ulcerative colitis (UC) than in those with Crohn’s disease (CD), according to the final 3-year data from the VEDOKIDS study.

Final VEDOKIDS data: Remission with maintenance vedolizumab durable in UC, less so in CD

14 Jun 2025

Functional abdominal pain in kids: Drotaverine, peppermint oil similar in head-to-head trial

13 Jun 2025 by

Both drotaverine and peppermint oil are safe and help alleviate abdominal pain in children whose pain cannot be attributed to a specific medical condition, with neither treatment demonstrating clear superiority over the other, according to the results of a single-blind, randomized controlled trial.

Functional abdominal pain in kids: Drotaverine, peppermint oil similar in head-to-head trial

13 Jun 2025

Fatigue prevalent in paediatric IBD patients

09 Jun 2025 by

Fatigue is more frequently reported in paediatric patients with inflammatory bowel disease (IBD) compared with controls and is associated with anaemia in a nationwide study.

Fatigue prevalent in paediatric IBD patients

09 Jun 2025